세계 세팔로스포린계 약제 시장 : 세대별, 투여 경로별, 용도별, 지역별, 국가별 분석, 시장 인사이트, 예측

Executive Summary

Azoth Analytics has released a research report titled "Global Cephalosporin Drug Market (2024 Edition)" which provides a complete analysis of the Global Cephalosporin Drug industry in terms of market segmentation By Generation (First Generation, Second Generation, Third Generation, Fourth Generation, Fifth Generation), By Route of Administration (Oral, Parenteral), By Application (Respiratory Tract Infection, Skin Infection, Urinary Tract Infection, Others), By Region (Americas , Europe, Asia-pacific, Middle-East & Africa), for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Italy, China, Japan, South Korea, India). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Cephalosporin Drug Market is expected to generate USD 21.9 Billion by the end of 2029, up from USD 13.27 Billion in 2022. A favourable growth element for the global Cephalosporin Drug market is propelled by the prevalence of bacterial infections, antibiotic resistance patterns, regulatory approvals, and the introduction of new formulations. During the forecast period, 2024-2029, Global Cephalosporin Drug is expected to expand at a CAGR of 7.5%. Pharmaceutical companies have focused on developing advanced generations of Cephalosporin drugs to combat bacterial resistance. The development of new generations, combination therapies, extended-release formulations, and expanded indications all contribute to the evolving landscape of Cephalosporin drugs.

The high and growing incidence of bacterial infections worldwide, such as respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections, is a significant driving factor. Cephalosporins are commonly prescribed antibiotics for treating these infections, which fuels the demand for Cephalosporin drugs.

The global pharmaceutical supply chains faced disruptions due to lockdowns, transportation restrictions, and factory closures during the pandemic. These disruptions affected the production, distribution, and availability of pharmaceutical products, including Cephalosporin drugs. However, efforts were made to mitigate the impact and ensure a continued supply of essential medications. Also, the pandemic disrupted ongoing clinical trials and delayed the initiation of new trials, including those related to the development of Cephalosporin drugs. This interruption may have impacted the timeline for introducing new Cephalosporins or exploring their expanded uses.

According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), Globally, the incidence of Upper Respiratory Infection reached 17*2 billion. Ongoing research involves the development of advanced drug delivery systems, such as inhalable formulations or novel respiratory devices. These technologies aim to enhance the targeted delivery of cephalosporin drugs to the respiratory tract, improving efficacy and minimizing side effects.

Extended-release formulations are designed to release the cephalosporin drug gradually over an extended period, allowing for less frequent dosing. This can lead to improved patient adherence and convenience. Advances in drug delivery technologies, such as controlled-release mechanisms, ensure a sustained therapeutic effect and potentially reduce the risk of side effects associated with rapid drug release.

Continuous manufacturing processes in pharmaceutical production offer advantages in terms of efficiency, cost-effectiveness, and quality control. Applying these processes to cephalosporin production contribute to a more streamlined and scalable manufacturing pipeline. Also, Smart packaging involves incorporating technologies like RFID (Radio-Frequency Identification) or QR codes to monitor drug storage conditions, track expiration dates, and enhance overall product integrity. This ensures the quality and stability of cephalosporin drugs throughout their lifecycle.

Scope of the Report

• The report analyses the Cephalosporin Drug Market by Value (USD Million).
• The report presents the analysis of the Cephalosporin Drug Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the Cephalosporin Drug Market by Generation (First Generation, Second Generation, Third Generation, Fourth Generation, Fifth Generation).
• The report analyses the Cephalosporin Drug Market by Route of Administration (Oral, Parenteral).
• The report analyses the Cephalosporin Drug Market by Application (Respiratory Tract Infection, Skin Infection, Urinary Tract Infection, Others).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.
• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Lupin Limited, Baxter International, F. Hoffmann-La Roche AG, Eli Lilly and Company, Abbott Laboratories, Merck & Co., Inc., Novartis, Sanofi, Pfizer, Teva Pharmaceutical.

Table of Contents

1. Market Background

• 1.1 Scope and Product Outlook
• 1.2 Executive Summary
• 1.3 Research Methodology

2. Strategic Recommendations

3. Global Cephalosporin Drug Market: Historic and Forecast (2019-2029)

• 3.1 Impact Analysis of Macro Economic Factors on Global Cephalosporin Drug Market
• 3.2 Pipeline Scenario
• 3.3 Global deaths associated with bacterial antimicrobial resistance
• 3.4 Epidemiology: Global Infectious Disease Prevalence
• 3.5 Epidemiology: Global Infectious Disease Incidence
• 3.6 Global Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
• 3.7 Degree of Impact of Covid-19 on Cephalosporin Drug Market
• 3.8 Global Cephalosporin Drug Market Segmentation : By Generation
  • 3.8.1 Global Cephalosporin Drug Market, By Generation Overview
  • 3.8.2 Global Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.8.3 Global Cephalosporin Drug Market Size, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.8.4 Global Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.8.5 Global Cephalosporin Drug Market Size, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.8.6 Global Cephalosporin Drug Market Size, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)
• 3.9 Global Cephalosporin Drug Market Segmentation : By Route of Administration
  • 3.9.1 Global Cephalosporin Drug Market, By Route of Administration Overview
  • 3.9.2 Global Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.9.3 Global Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
• 3.10 Global Cephalosporin Drug Market Segmentation : By Application
  • 3.10.1 Global Cephalosporin Drug Market, By Application Overview
  • 3.10.2 Global Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.10.3 Global Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.10.4 Global Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.10.5 Global Cephalosporin Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)

4. Global Cephalosporin Drug Market, Regional Analysis

• 4.1 Regional Coverage of the Study
• 4.2 Regional Snapshot

5. Americas Cephalosporin Drug Market: Historic and Forecast (2019-2029)

• 5.1 Americas Cephalosporin Drug Market: Snapshot
• 5.2 Americas Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
• 5.3 Americas Cephalosporin Drug Market: Key Factors
• 5.4 Americas Cephalosporin Drug Market: Segment Analysis
• 5.5 Americas Cephalosporin Drug Market Segmentation : By Generation
  • 5.5.1 Americas Cephalosporin Drug Market, By Generation Overview
  • 5.5.2 Americas Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.5.3 Americas Cephalosporin Drug Market Size, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.5.4 Americas Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.5.5 Americas Cephalosporin Drug Market Size, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.5.6 Americas Cephalosporin Drug Market Size, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)
• 5.6 Americas Cephalosporin Drug Market Segmentation : By Route of Administration
  • 5.6.1 Americas Cephalosporin Drug Market, By Route of Administration Overview
  • 5.6.2 Americas Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.6.3 Americas Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
• 5.7 Americas Cephalosporin Drug Market Segmentation : By Application
  • 5.7.1 Americas Cephalosporin Drug Market, By Application Overview
  • 5.7.2 Americas Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.7.3 Americas Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.7.4 Americas Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.7.5 Americas Cephalosporin Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
• 5.8 Americas Cephalosporin Drug Market Segmentation : By Country
  • 5.8.1 Americas Cephalosporin Drug Market, By Country Overview
  • 5.8.2 United States Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 5.8.2.1 United States Cephalosporin Drug Market, By Generation
    • 5.8.2.2 United States Cephalosporin Drug Market, By Route of Administration
    • 5.8.2.3 United States Cephalosporin Drug Market, By Application
  • 5.8.3 Canada Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 5.8.3.1 Canada Cephalosporin Drug Market, By Generation
    • 5.8.3.2 Canada Cephalosporin Drug Market, By Route of Administration
    • 5.8.3.3 Canada Cephalosporin Drug Market, By Application
  • 5.10.4 Rest of Americas Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 5.10.4.1 Rest of Americas Cephalosporin Drug Market, By Generation
    • 5.10.4.2 Rest of Americas Cephalosporin Drug Market, By Route of Administration
    • 5.10.4.3 Rest of Americas Cephalosporin Drug Market, By Application

6. Europe Cephalosporin Drug Market: Historic and Forecast (2019-2029)

• 6.1 Europe Cephalosporin Drug Market: Snapshot
• 6.2 Europe Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
• 6.3 Europe Cephalosporin Drug Market: Key Factors
• 6.4 Europe Cephalosporin Drug Market: Segment Analysis
• 6.5 Europe Cephalosporin Drug Market Segmentation : By Generation
  • 6.5.1 Europe Cephalosporin Drug Market, By Generation Overview
  • 6.5.2 Europe Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.5.3 Europe Cephalosporin Drug Market Size, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.5.4 Europe Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.5.5 Europe Cephalosporin Drug Market Size, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.5.6 Europe Cephalosporin Drug Market Size, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)
• 6.6 Europe Cephalosporin Drug Market Segmentation : By Route of Administration
  • 6.6.1 Europe Cephalosporin Drug Market, By Route of Administration Overview
  • 6.6.2 Europe Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.6.3 Europe Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
• 6.7 Europe Cephalosporin Drug Market Segmentation : By Application
  • 6.7.1 Europe Cephalosporin Drug Market, By Application Overview
  • 6.5.2 Europe Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.5.3 Europe Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.5.4 Europe Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.7.5 Europe Cephalosporin Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
• 6.8 Europe Cephalosporin Drug Market Segmentation : By Country
  • 6.8.1 Europe Cephalosporin Drug Market, By Country Overview
  • 6.8.2 United Kingdom Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.2.1 United Kingdom Cephalosporin Drug Market, By Generation
    • 6.8.2.2 United Kingdom Cephalosporin Drug Market, By Route of Administration
    • 6.8.2.3 United Kingdom Cephalosporin Drug Market, By Application
  • 6.8.3 Germany Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.3.1 Germany Cephalosporin Drug Market, By Generation
    • 6.8.3.2 Germany Cephalosporin Drug Market, By Route of Administration
    • 6.8.3.3 Germany Cephalosporin Drug Market, By Application
  • 6.8.4 France Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.4.1 France Cephalosporin Drug Market, By Generation
    • 6.8.4.2 France Cephalosporin Drug Market, By Route of Administration
    • 6.8.4.3 France Cephalosporin Drug Market, By Application
  • 6.8.5 Italy Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.5.1 Italy Cephalosporin Drug Market, By Generation
    • 6.8.5.2 Italy Cephalosporin Drug Market, By Route of Administration
    • 6.8.5.3 Italy Cephalosporin Drug Market, By Application
  • 6.8.6 Rest of Europe Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 6.8.6.1 Rest of Europe Cephalosporin Drug Market, By Generation
    • 6.8.6.2 Rest of Europe Cephalosporin Drug Market, By Route of Administration
    • 6.8.6.3 Rest of Europe Cephalosporin Drug Market, By Application

7. Asia Pacific Cephalosporin Drug Market: Historic and Forecast (2019-2029)

• 7.1 Asia Pacific Cephalosporin Drug Market: Snapshot
• 7.2 Asia Pacific Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
• 7.3 Asia Pacific Cephalosporin Drug Market: Key Factors
• 7.4 Asia Pacific Cephalosporin Drug Market: Segment Analysis
• 7.5 Asia Pacific Cephalosporin Drug Market Segmentation : By Generation
  • 7.5.1 Asia Pacific Cephalosporin Drug Market, By Generation Overview
  • 7.5.2 Asia Pacific Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.5.3 Asia Pacific Cephalosporin Drug Market Size, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.5.4 Asia Pacific Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.5.5 Asia Pacific Cephalosporin Drug Market Size, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.5.6 Asia Pacific Cephalosporin Drug Market Size, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)
• 7.6 Asia Pacific Cephalosporin Drug Market Segmentation : By Route of Administration
  • 7.6.1 Asia Pacific Cephalosporin Drug Market, By Route of Administration Overview
  • 7.6.2 Asia Pacific Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.6.3 Asia Pacific Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
• 7.7 Asia Pacific Cephalosporin Drug Market Segmentation : By Application
  • 7.7.1 Asia Pacific Cephalosporin Drug Market, By ApplicationOverview
  • 7.7.2 Asia Pacific Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.7.3 Asia Pacific Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.7.4 Asia Pacific Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.7.5 Asia Pacific Cephalosporin Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
• 7.8 Asia Pacific Cephalosporin Drug Market Segmentation : By Country
  • 7.8.1 Asia Pacific Cephalosporin Drug Market, By Country Overview
  • 7.8.2 China Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.2.1 China Cephalosporin Drug Market, By Generation
    • 7.8.2.2 China Cephalosporin Drug Market, By Route of Administration
    • 7.8.2.3 China Cephalosporin Drug Market, By Application
  • 7.8.3 Japan Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.3.1 Japan Cephalosporin Drug Market, By Generation
    • 7.8.3.2 Japan Cephalosporin Drug Market, By Route of Administration
    • 7.8.3.3 Japan Cephalosporin Drug Market, By Application
  • 7.8.4 South Korea Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.4.1 South Korea Cephalosporin Drug Market, By Generation
    • 7.8.4.2 South Korea Cephalosporin Drug Market, By Route of Administration
    • 7.8.4.3 South Korea Cephalosporin Drug Market, By Application
  • 7.8.5 India Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.5.1 India Cephalosporin Drug Market, By Generation
    • 7.8.5.2 India Cephalosporin Drug Market, By Route of Administration
    • 7.8.5.3 India Cephalosporin Drug Market, By Application
  • 7.8.6 Rest of Asia Pacific Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
    • 7.8.6.1 Rest of Asia Pacific Cephalosporin Drug Market, By Generation
    • 7.8.6.2 Rest of Asia Pacific Cephalosporin Drug Market, By Route of Administration
    • 7.8.6.3 Rest of Asia Pacific Cephalosporin Drug Market, By Application

8. Middle East and Africa Cephalosporin Drug Market: Historic and Forecast (2019-2029)

• 8.1 Middle East and Africa Cephalosporin Drug Market: Snapshot
• 8.2 Middle East and Africa Cephalosporin Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
• 8.3 Middle East and Africa Cephalosporin Drug Market: Key Factors
• 8.4 Middle East and Africa Cephalosporin Drug Market: Segment Analysis
• 8.5 Middle East and Africa Cephalosporin Drug Market Segmentation : By Generation
  • 8.5.1 Middle East and Africa Cephalosporin Drug Market, By Generation Overview
  • 8.5.2 Middle East and Africa Cephalosporin Drug Market Size, By First Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.5.3 Middle East and Africa Cephalosporin Drug Market, By Second Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.5.4 Middle East and Africa Cephalosporin Drug Market Size, By Third Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.5.5 Middle East and Africa Cephalosporin Drug Market, By Fourth Generation, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.5.6 Middle East and Africa Cephalosporin Drug Market, By Fifth Generation, By Value, 2019H-2029F (USD Million & CAGR)
• 8.6 Middle East and Africa Cephalosporin Drug Market Segmentation : By Route of Administration
  • 8.6.1 Middle East and Africa Cephalosporin Drug Market, By Route of Administration Overview
  • 8.6.2 Middle East and Africa Cephalosporin Drug Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.6.3 Middle East and Africa Cephalosporin Drug Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
• 8.7 Middle East and Africa Cephalosporin Drug Market Segmentation : By Application
  • 8.7.1 Middle East and Africa Cephalosporin Drug Market, By Application Overview
  • 8.7.2 Middle East and Africa Cephalosporin Drug Market Size, By Respiratory Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.7.3 Middle East and Africa Cephalosporin Drug Market Size, By Skin Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.7.4 Middle East and Africa Cephalosporin Drug Market Size, By Urinary Tract Infection, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.7.5 Middle East and Africa Cephalosporin Drug Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

• 9.1 Impact Assessment of Market Dynamics on the Global Cephalosporin Drug Market
• 9.2 Drivers
• 9.3 Restraints
• 9.4 Trends

10. Industry Ecosystem Analysis

• 10.1 Porter's Five Forces Analysis

11. Competitive Positioning

• 11.1 Companies' Product Positioning
• 11.2 Market Share of Leading Companies
• 11.3 Company Profiling
  • 11.3.1 Lupin Limited
  • 11.3.2 Baxter International
  • 11.4.3 F. Hoffmann-La Roche AG
  • 11.3.4 Eli Lilly and Company
  • 11.3.5 Abbott Laboratories
  • 11.3.6 Merck & Co., Inc.
  • 11.3.7 Novartis
  • 11.3.8 Sanofi
  • 11.3.9 Pfizer
  • 11.3.10 Teva Pharmaceutical